富蘭克林坦伯頓全球投資系列-生技領航基金美元Z(acc)股
14.77美元0.09(0.61%)
2024/12/20更新
績效 / 1月2.59%
3月14.15%
1年8.58%
晨星評等-
- 1.現金3.47%
- 2.股票12.27%
- 3.債券0.00%
- 4.其他84.26%
- 1.美國83.78%
- 2.歐元區4.15%
- 3.英國4.10%
- 4.歐洲不包含歐元區3.02%
- 5.加拿大0.92%
- 1.Vertex Pharmaceuticals Inc6.26%
- 2.Amgen Inc6.07%
- 3.Regeneron Pharmaceuticals Inc5.42%
- 4.Gilead Sciences Inc5.23%
- 5.Intra-Cellular Therapies Inc3.54%
- 6.argenx SE ADR3.25%
- 7.Jazz Pharmaceuticals PLC3.06%
- 8.Federal Home Loan Banks2.92%
- 9.AstraZeneca PLC ADR2.70%
- 10.Merus NV2.61%
- 1.現金3.47%
- 2.股票12.27%
- 3.債券0.00%
- 4.其他84.26%
- 1.美國83.78%
- 2.歐元區4.15%
- 3.英國4.10%
- 4.歐洲不包含歐元區3.02%
- 5.加拿大0.92%
- 1.Vertex Pharmaceuticals Inc6.26%
- 2.Amgen Inc6.07%
- 3.Regeneron Pharmaceuticals Inc5.42%
- 4.Gilead Sciences Inc5.23%
- 5.Intra-Cellular Therapies Inc3.54%
- 6.argenx SE ADR3.25%
- 7.Jazz Pharmaceuticals PLC3.06%
- 8.Federal Home Loan Banks2.92%
- 9.AstraZeneca PLC ADR2.70%
- 10.Merus NV2.61%